NCT03822845View on ClinicalTrials.gov

Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

March 30, 2021

Study Completion Date

March 30, 2021

Conditions
Prostatic NeoplasmsProstatic Neoplasms, Castration-Resistant
Interventions
DRUG

Ga-68 PSMA-HBED-CC PET

Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.

Trial Locations (1)

52242

The University of Iowa Hospitals & Clinics, Iowa City

All Listed Sponsors
lead

Michael Graham PhD, MD

OTHER

NCT03822845 - Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer | Biotech Hunter | Biotech Hunter